Saltar al contenido
Merck

SML0216

Sigma-Aldrich

Brinzolamide

≥98% (HPLC)

Sinónimos:

(5R)-5-Ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2?6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide, (R)- 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide, AL 4862

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

10 MG
MXP 2,692.00
50 MG
MXP 8,598.00

MXP 2,692.00


Check Cart for Availability

Solicitar un pedido a granel

Seleccione un Tamaño

Cambiar Vistas
10 MG
MXP 2,692.00
50 MG
MXP 8,598.00

About This Item

Fórmula empírica (notación de Hill):
C12H21N3O5S3
Número de CAS:
Peso molecular:
383.51
Número MDL:
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77

MXP 2,692.00


Check Cart for Availability

Solicitar un pedido a granel

Ensayo

≥98% (HPLC)

Formulario

powder

condiciones de almacenamiento

desiccated

color

white to beige

solubilidad

DMSO: ≥10 mg/mL

temp. de almacenamiento

−20°C

cadena SMILES

CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O

InChI

1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1

Clave InChI

HCRKCZRJWPKOAR-JTQLQIEISA-N

Información sobre el gen

human ... CA2(760)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Brinzolamide is a small molecular weight compound that has an ability to bind melanin. This drug is used in ocular therapy.[1]

Aplicación

Brinzolamide has been used as a melanin binding compound or drug in melanin binding assays.[1] It has also been used as a carbonic anhydrase inhibitor (CAI).[2]

Acciones bioquímicas o fisiológicas

Brinzolamide is a carbonic anhydrase II inhibitor
Brinzolamide is a carbonic anhydrase II inhibitor used to lower intraocular pressure.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

James F T Li Yim et al.
Current medical research and opinion, 27(8), 1499-1502 (2011-06-10)
To determine the intraocular pressure (IOP) lowering effect of brinzolamide when added to latanoprost. Patients who were simultaneously on brinzolamide and latanoprost were identified from the large prospective database of patients diagnosed with primary open angle glaucoma, normal tension glaucoma
Rajendra S Kadam et al.
Drug metabolism and disposition: the biological fate of chemicals, 39(9), 1529-1537 (2011-06-16)
Ophthalmic carbonic anhydrase inhibitors have been shown to improve retinal and optic nerve blood flow. However, the relative tissue distributions of commercially available carbonic anhydrase inhibitors to the optic nerve are not known. The objective of this study was to
Risto S Cvetkovic et al.
Drugs & aging, 20(12), 919-947 (2003-10-21)
Brinzolamide is a highly specific carbonic anhydrase (CA) inhibitor which lowers intraocular pressure (IOP) by reducing the rate of aqueous humour formation. Formulated as a 1% ophthalmic suspension (Azopt) and administered twice or three times daily, brinzolamide is indicated for
L DeSantis
Survey of ophthalmology, 44 Suppl 2, S119-S129 (2000-02-09)
The development of topically active carbonic anhydrase inhibitors (CAIs) is a significant recent achievement in glaucoma medical treatment. Brinzolamide, the newest topical CAI, exhibits selectivity, high affinity, and potent inhibitory activity for the carbonic anhydrase type II isozyme (CA-II), which
Louis F Dell'osso et al.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 31(3), 228-233 (2011-06-29)
Recent advances in infantile nystagmus syndrome (INS) surgery have uncovered the therapeutic importance of proprioception. In this report, we test the hypothesis that the topical carbonic anhydrase inhibitor (CAI) brinzolamide (Azopt) has beneficial effects on measures of nystagmus foveation quality

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico